Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in high-risk smoldering multiple myeloma
jRCT2031210017Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Aug 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of isatuximab, lenalidomide and dexamethasone in smoldering multiple myeloma (SMM) and multiple myeloma (MM), sponsored by Sanofi. Primary endpoints: Safety assessment: adverse events, Plasma concentration of isatuximab: Cmax and 2 more. Started Aug 2021; status: active, not recruiting.
02
Drugs
isatuximablenalidomidedexamethasone
03
Conditions
smoldering multiple myeloma (SMM)multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031210017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210017.